This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at firstname.lastname@example.org or call 800-767-3771 ext. 9339.
Recently, dental lasers’ manufacturer and distributor, BIOLASE, Inc. was awarded a new patent for its non-contact laser hand piece for tissue cutting by the U.S. Patent and Trademark Office, which further strengthened its position in the laser dentistry market.
The patent titled “Non-Contact Handpiece for Laser Tissue” is for Biolase’s non-contact hand piece for cutting both hard and soft tissue using its WaterLase all tissue lasers.
According to the company, the non-contact laser hand piece is designed to provide high-density uniform laser beam from a particular distance to the target tissue. Owing to this feature of the product, back reflections and inefficiency can be reduced while operating on the tissues. The company further believes that they have an edge over its competitors since non-contact laser handpiece is user-replaceable and can be configured according to the optimal operational distance and focal spot sizes.
The new patent comes on the heels of FDA clearance for Biolase’s EPIC 10S soft tissue diode laser issued earlier this week.
BIOLASE develops and markets lasers and related products for applications in medicine and dentistry. Its key products, the dental laser systems, perform a broad spectrum of dental procedures, including cosmetic and complex surgical applications. To date the company has worked with over 340 patents and patent pending technologies made to deliver efficient performance with speed, less pain and more efficiency. To date, the company has sold more than 22,000 lasers.
Currently, Biolase carries a Zacks Rank #3 (Hold). Other medical and laser instrument stocks worth considering are Cepheid (CPHD - Analyst Report), GSI Group Inc. (GSIG - Snapshot Report) and Cynosure, Inc. (CYNO - Snapshot Report). While Cepheid carries a Zacks Rank #1 (Buy), GSI Group and Cynosure carry a Zacks Rank #2 (Buy).